Study of Erenumab (AMG 334) in Women With Hot Flashes

Completed · Phase 1 · Has a placebo group

Conditions studied: Vasomotor Symptoms; Hot Flashes

In brief

The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.

Key facts

Study ID

NCT01890109

Run by

Amgen

People needed

103

Starts

2013-05-13

Expected to finish

2014-03-11

Last updated by the study team

2019-01-14

Who can join

Age: 45 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• female subjects with hot flashes associated with menopause between 45 and 65 years of age, inclusive, with no history or evidence of clinically relevant medical disorders as determined by the investigator in consultation with the Amgen physician.

You may not qualify if…

• History or evidence of clinically significant disorder (including psychiatric), condition or disease that, in the opinion of the Investigator or Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Where it is running

• Research Site — San Diego, California, United States
• Research Site — Miami, Florida, United States
• Research Site — Winston-Salem, North Carolina, United States
• Eugene Andruczyk — Philadelphia, Pennsylvania, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Mt. Pleasant, South Carolina, United States
• Research Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.